References
- Aries CA, Murray BE. Antibiotic-resistant bugs in the 21st Century – a clinical super-challenge. N. Engl. J. Med.360(5), 439–443 (2009).
- Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect.10(Suppl. 4), 18–22 (2004).
- Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest118(1), 146–155 (2000).
- Soriano A, Marco F, Martínez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.46(2), 193–200 (2008).
- Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis.43(1), 25–31 (2006).
- Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis.44(2), 159–177 (2007).
- Souvenir D, Anderson DE Jr, Palpant S et al. Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J. Clin. Microbiol.36(7), 1923–1926 (1998).
- Sobel JD. Changing epidemiology of invasive candidiasis in intensive care units – much ado about nothing? Crit. Care Med.36(7), 2188–2189 (2008).
- Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N. Engl. J. Med.355(7), 653–665 (2006).
- Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347(25), 2020–2029 (2002).
- Stender H. PNA FISH: an intelligent stain for rapid diagnosis of infectious diseases. Expert Rev. Mol. Diagn.3(5), 649–655 (2003).
- Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J. Antimicrob. Chemother.58(1), 154–158 (2006).
- Ly T, Gulia J, Pyrgos V, Waga M, Shoham S. Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Ther. Clin. Risk Manag.4(3), 637–640 (2008).
- Forrest GN, Roghmann MC, Toombs LS et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob. Agents Chemother.52(10), 3558–3563 (2008).
- Forrest GN, Mankes K, Jabra-Rizk MA et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J. Clin. Microbiol.44(9), 3381–3383 (2006).
- Della-Latta P, Whittier S, Wu F. Impact of rapid identification of C. albicans and C. glabrata directly from blood cultures using PNA FISH technology on selection of antifungal therapy. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 19–22 April 2008.
- Sims SV, Sekeres JK, Shrestha NK. Impact of Candida albicans peptide nucleic acid hybridization (PNA FISH) on antifungal usage at Cleveland Clinic. Presented at: 47th Meeting of the Infectious Diseases Society of America. Philadelphia, PA, USA, 29 October–1 November 2009.